Epithelial–Mesenchymal Transition in Cancer: Insights Into Therapeutic Targets and Clinical Implications
MedComm · 2025-09 · 6 (9)
DOI: 10.1002/mco2.70333 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 29.08.2025. Verfasst von Dhasarathdev Srinivasan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Advanced Biotherapeutics and Regenerative Medicine Faculty of Research Chettinad Hospital and Research Institute Chettinad Academy of Rese…. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Radiation therapy is a fundamental component of cancer treatment, benefiting 50%–70% of patients by selectively targeting malignant tissues. However, radioresistance remains a significant challenge, often driven by epithelial–mesenchymal transition (EMT). EMT increases cancer invasiveness and metastasis by upregulating mesenchymal markers, including vimentin and N‐cadherin, and downregulating epithelial markers, such as E‐cadherin. EMT under radiation involves principal signaling pathways, including TGF‐β, Wnt/β‐catenin, Notch, and ERK, which regulate EMT through transcription factors such as Snail, Slug, Twist, and Zeb1/2. These alterations drive cytoskeletal reorganization, decrease cell–cell adhesion, and enhance extracellular matrix degradation via integrins, MMP‐2, and MMP‐9. We also explored how growth hormones, inflammatory cytokines, and hypoxia in the tumor microenvironment affect radiation‐induced EMT. Targeting EMT pathways with monoclonal antibodies and small‐molecule inhibitors of signaling pathways may help overcome radioresistance. However, due to the dual role of EMT in cancer progression and tissue regeneration, precise treatment strategies are essential. There is a lack of comprehensive multi‐omics studies that provide insights into postradiation EMT progression. This review examines how radiation induces EMT and its impact on metastasis and immune responses while also proposing therapeutic approaches. Integrating EMT‐targeting strategies with existing cancer treatments could enhance the effectiveness of radiotherapy and improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Advanced Biotherapeutics and Regenerative Medicine Faculty of Research Chettinad Hospital and Research Institute Chettinad Academy of Research and Education Kelambakkam Tamil Nadu India.
- Centre for Herbal Pharmacology and Environmental Sustainability Chettinad Hospital and Research Institute Chettinad Academy of Research and Education Kelambakkam Tamil Nadu India.
- Department of Biomedical Sciences The Apollo University Chittoor Andhra Pradesh India.
- Vopec Pharmaceuticals Pvt. Limited Research and Development Division Chennai India.
- Department of Internal Medicine Berkshire Medical Center Pittsfield Massachusetts USA.
- Department of Natural and Applied Sciences Nexus Institute of Research and Innovation (NIRI) Lalitpur Nepal.
ORCID-Profile: Rupendra Shrestha
Zitieren
APA
Srinivasan, D., Balakrishnan, R., Chauhan, A., Kumar, J., Girija, D. M., Shrestha, R., Shrestha, R., & Subbarayan, R. (2025). Epithelial–Mesenchymal Transition in Cancer: Insights Into Therapeutic Targets and Clinical Implications. MedComm, 6(9). https://doi.org/10.1002/mco2.70333
Vancouver
Srinivasan D, Balakrishnan R, Chauhan A, Kumar J, Girija DM, Shrestha R, et al. Epithelial–Mesenchymal Transition in Cancer: Insights Into Therapeutic Targets and Clinical Implications. MedComm. 2025;6(9). doi:10.1002/mco2.70333
BibTeX
@article{Srinivasan2025,
author = {Srinivasan, Dhasarathdev and Balakrishnan, Ranjith and Chauhan, Ankush and Kumar, Jeevan and Girija, Dinesh Murugan and Shrestha, Reena and Shrestha, Rupendra and Subbarayan, Rajasekaran},
title = {Epithelial–Mesenchymal Transition in Cancer: Insights Into Therapeutic Targets and Clinical Implications},
journal = {MedComm},
year = {2025},
volume = {6},
number = {9},
doi = {10.1002/mco2.70333}
}
EUVIMED